Clinical Trial

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a randomized, controlled, open-label, multicenter, Phase Ⅲ clinical study designed to compare the efficacy and safety of KN026 combined with HB1801 and chemotherapy versus trastuzumab combined with pertuzumab and chemotherapy as adjuvant therapy in participants with HER2-positive breast cancer.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-09
Trial Details
NCT Number NCT07441460
Lead Sponsor Shanghai JMT-Bio Inc.
Conditions Resectable HER2-positive Breast Cancer
Enrollment 1,800 participants
Start Date 2026-03-06
Primary Completion 2034-08-07 (estimated)
Study Completion 2035-08-07 (estimated)
Updated on ClinicalTrials.gov 2026-04-08